| 0.9901 -0.06 (-5.7%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.46 | 1-year : | 1.69 |
| Resists | First : | 1.25 | Second : | 1.45 |
| Pivot price | 1.17 |
|||
| Supports | First : | 0.94 | Second : | 0.78 |
| MAs | MA(5) : | 1.05 |
MA(20) : | 1.17 |
| MA(100) : | 1.26 |
MA(250) : | 2.58 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 12.8 |
D(3) : | 13.4 |
| RSI | RSI(14): 35 |
|||
| 52-week | High : | 9.6 | Low : | 0.67 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ABVC ] has closed above bottom band by 8.9%. Bollinger Bands are 13.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.04 - 1.05 | 1.05 - 1.05 |
| Low: | 0.95 - 0.96 | 0.96 - 0.96 |
| Close: | 0.98 - 0.99 | 0.99 - 1 |
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
Thu, 18 Apr 2024
AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33 M, With 1.66 M AiBtl Shares at $5 per Share - GlobeNewswire
Thu, 18 Apr 2024
ABVC BioPharma's AiBtl BioPharma acquires TT Life Company - TipRanks.com - TipRanks
Wed, 17 Apr 2024
ABVC BioPharma inks licensing deal for cancer drug - Investing.com South Africa
Wed, 17 Apr 2024
ABVC BioPharma executes licensing agreement with OncoX (NASDAQ:ABVC) - Seeking Alpha
Wed, 17 Apr 2024
ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate ... - GlobeNewswire
Thu, 11 Apr 2024
Short Interest in ABVC BioPharma, Inc. (NASDAQ:ABVC) Expands By 1146.5% - Defense World
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 6.8e+006 (%) |
| Held by Institutions | 26.9 (%) |
| Shares Short | 151 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.19e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -90 % |
| Return on Assets (ttm) | 605.5 % |
| Return on Equity (ttm) | -42.7 % |
| Qtrly Rev. Growth | 152430 % |
| Gross Profit (p.s.) | -129.36 |
| Sales Per Share | -249.3 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.71 |
| Dividend | 0 |
| Forward Dividend | 1.32e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|